Virtual Reality and Spinal Stimulation to Improve Arm Function

Sponsor
Virginia Commonwealth University (Other)
Overall Status
Withdrawn
CT.gov ID
NCT05065437
Collaborator
(none)
0
1
1
19
0

Study Details

Study Description

Brief Summary

The main objective of our work is to develop and test the safety and feasibility of a home-based upper limb rehabilitation program for individuals with tetraplegia. The program will consist of simultaneous non-invasive spinal cord stimulation and immersive virtual exercises of the upper limbs, with a focus on shoulder and elbow function.

Condition or Disease Intervention/Treatment Phase
  • Other: Active (Virtual reality and spinal stimulation)
N/A

Study Design

Study Type:
Interventional
Actual Enrollment :
0 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
Immersive Virtual Reality and Noninvasive Spinal Stimulation to Promote Arm Function in Individuals With Tetraplegia
Anticipated Study Start Date :
Jun 1, 2022
Anticipated Primary Completion Date :
Jan 1, 2024
Anticipated Study Completion Date :
Jan 1, 2024

Arms and Interventions

Arm Intervention/Treatment
Experimental: Virtual reality and spinal stimulation

Safety and feasibility of a virtual reality and spinal stimulation intervention will be tested.

Other: Active (Virtual reality and spinal stimulation)
Each session is 25 minutes; 5 minutes of setup, and 20 minutes of simultaneous spinal stimulation at the cervical level and immersive virtual experience/gameplay.

Outcome Measures

Primary Outcome Measures

  1. Change in medical status [Baseline to post intervention, approximately 4 weeks]

    Safety of the intervention will be assessed as the number of participants who experience a reduction in medical stability and/or functionality from before to after the intervention.

  2. Acceptability of the treatment [Post intervention, approximately 4 weeks]

    Acceptability of the treatment will be assessed using the Treatment Evaluation Inventory-Short Form. Items are scored using a 5-point scale, with 1 equaling strongly disagree and 5 equaling strongly agree. TEI-SF scores can range from 9 to 45, with higher scores representing greater acceptance of the treatment.

  3. Usability of the treatment [Post intervention, approximately 4 weeks]

    Usability of the treatment will be assessed using the Usefulness, Satisfaction, and Ease of Use (USE) Questionnaire. Items are rated on a seven-point scale ranging from strongly disagree to strongly agree. A higher scale score indicates higher usability.

Secondary Outcome Measures

  1. Change in affect [Baseline to post intervention, approximately 4 weeks]

    Affect will be assessed using the Positive and Negative Affect Schedule (PANAS). The PANAS is a 20-item measure that measures the intensity of 20 emotions on a 0-5 scale ranging from "not at all" to "extremely."

  2. Change in current pain intensity [Baseline to post intervention, approximately 4 weeks]

    Current pain intensity will be assessed using a Numeric Rating Scale (NRS). Participants will rate their current pain (multiple types of pain) on a 0-10 scale (0 = "no pain" and 10 = "worst possible pain").

  3. Change in clinical muscle strength [Baseline to post intervention, approximately 4 weeks]

    Clinical muscle strength will be assessed using the American Spinal Cord Injury Association (ASIA) Upper Extremity Motor Score. Motor strength is rated on a 6 point scale with higher ratings indicating greater strength.

  4. Change in upper limb function [Baseline to post intervention, approximately 4 weeks]

    Upper limb function will be assessed using the Spinal Cord Independence Measure (SCIM). The SCIM is composed of 19 items that assess function. SCIM scores range from 0 to 100.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 70 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  1. incomplete low tetraplegia (C5-8; [ASIA] classification B-D),

  2. free of contraindications to transspinal stimulation,

  3. more than one-year post-injury,

  4. stable medication regimen for the past month,

  5. utilization of wheelchair as a primary mode of mobility (>75% of the time). -

Exclusion Criteria:
  1. Neurologic injury other than spinal cord injury

  2. severe medical illness.

Contacts and Locations

Locations

Site City State Country Postal Code
1 Virginia Commonwealth University Richmond Virginia United States 23298

Sponsors and Collaborators

  • Virginia Commonwealth University

Investigators

  • Principal Investigator: Carrie Peterson, PhD, Virginia Commonwealth University

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Virginia Commonwealth University
ClinicalTrials.gov Identifier:
NCT05065437
Other Study ID Numbers:
  • FP00015240
First Posted:
Oct 4, 2021
Last Update Posted:
Jul 1, 2022
Last Verified:
Jun 1, 2022
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Virginia Commonwealth University
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jul 1, 2022